GlassScriptPhysician profile
Wanhua Yang
NPI 1922360627
$1,732.61
in general payments reported to CMS, 2019-2025
30 companies · $201 in 2025
The $201 reported for 2025 was more than what 79% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $202 · 2021: $371 · 2022: $146 · 2023: $106 · 2024: $132 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $439.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $208.57 | 2019-2025 | Lynparza, Enhertu |
| Novartis Pharmaceuticals Corporation | $125.56 | 2019-2023 | |
| Celgene Corporation | $116.55 | 2019-2024 | Reblozyl |
| Merck Sharp & Dohme LLC | $104.93 | 2019-2021 | |
| Daiichi Sankyo INC. | $102.00 | 2020-2025 | Enhertu, Datroway |
| Haemonetics Corporation | $96.56 | 2019 | |
| Amgen INC. | $91.60 | 2019-2021 | |
| Pfizer INC. | $87.89 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.17 | 2019-2021 | |
| Eisai INC. | $71.64 | 2019-2021 | |
| Lilly USA, LLC | $70.77 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $57.56 | 2019-2022 | |
| Seagen INC. | $53.03 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $51.48 | 2020-2022 | |
| Servier Pharmaceuticals LLC | $48.41 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $47.04 | 2019 | |
| Gilead Sciences, INC. | $46.68 | 2025 | Trodelvy |
| Tempus Ai, INC | $29.23 | 2025 | Xt Cdx |
| Alexion Pharmaceuticals, INC. | $22.65 | 2022 | |
| Beckman Coulter, INC. | $21.45 | 2025 | Dxh 900 Hematology System |
| Genentech USA, INC. | $21.40 | 2025 | Itovebi |
| Glaxosmithkline, LLC. | $21.36 | 2024 | Ojjaara |
| Beigene USA, INC. | $20.23 | 2021 | |
| Foundation Medicine, INC. | $20.22 | 2019 | |
| Exelixis INC. | $19.44 | 2020 | |
| Janssen Biotech, INC. | $19.01 | 2019 | |
| Medtronic USA, INC. | $18.96 | 2019 | |
| Medline Industries LP | $17.69 | 2024 | |
| Jazz Pharmaceuticals INC. | $17.64 | 2021 | |
| Incyte Corporation | $15.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wanhua Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.